An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE).

drug protocol number
CRAD001LIC01
drug sponsor
Novartis
drug study
RAD001 (Everolimus)
drug trial site
KFSH & RC-R
drug status
Rejected
drug phase